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Abstract
Background—Syphilis management is complex and demonstration of treatment response 
requires monitoring of nontreponemal antibody titers for a ≥ 4-fold decline and/or seroreversion to 
nonreactive titers.
Methods—We evaluated data from a multi-center clinical trial of syphilis treatment conducted 
from 2000–2009 involving HIV-negative patients age ≥ 18 years with early syphilis. To assess the 
rate of titer decline and seroreversion after effective therapy, rapid plasma reagin (RPR) titers were 
analyzed at 1, 3, 6, 9 and 12 months among patients with an appropriate treatment response. We 
plotted the rate of RPR titer decline after treatment, estimated the frequency of seroreversion, and 
conducted multivariate analyses to assess characteristics associated with seroreversion.
Results—Among 369/465 (79.4%) HIV-negative patients with early syphilis who had an 
appropriate treatment response, 333 participants had complete RPR data over 12 months. 
Although the decline in RPR titers was ≥ 4-fold among 88.0% (293/333) of participants at 3 
months and ≥ 8-fold among 77.8% at 6 months, only 9.6% achieved complete RPR seroreversion 
at 6 months and 17.1% at 12 months after therapy. Male gender (adjusted odds ratio [AOR]: 4.3, 
95% confidence interval [CI]: 1.8, 10.5) and baseline RPR titers ≤ 1:32 (AOR: 14.5; 95% CI: 6.8, 
31.2) were associated with higher odds of seroreversion compared to females and titers > 1:32, 
respectively.
Corresponding Author and Reprints: Arlene C. Seña, MD, MPH, The University of North Carolina at Chapel Hill, Division of 
Infectious Diseases, CB #7030, 130 Mason Farm Road, Phone: 919-966-2536, Fax: 919-966-6714, idrod@med.unc.edu. 
Conflict of Interest: Dr. Hook reports personal fees from Rib-X (Melinta), grants from Cempra, grants from Becton Dickinson, grants 
from Hologic, personal fees from Roche Molecular, personal fees from McGraw Hill, personal fees from Cepheid, outside the 
submitted work. All other authors declare no conflict of interests.
HHS Public Access
Author manuscript
Sex Transm Dis. Author manuscript; available in PMC 2018 January 01.
Published in final edited form as:





















Conclusions—Despite a ≥ 4-fold RPR titer decline after treatment, the majority of HIV-negative 
patients with early syphilis failed to have seroreversion at 12 months. Nontreponemal antibody 
titers often persist despite an appropriate treatment response.
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Introduction
The syphilis epidemic is unrelenting and now disproportionately involves men who have sex 
with men (MSM) in the United States and Western Europe. Traditional syphilis screening 
and monitoring of therapeutic response rely heavily on serological nontreponemal antibody 
titers, due to our inability to culture Treponema pallidum subsp. pallidum in vitro. 
Resolution of signs and symptoms after treatment of primary or secondary syphilis is 
indicative of response to therapy. However, serological follow-up is recommended for all 
patients to determine an appropriate serological treatment response defined as ≥ four-fold (or 
two dilutions; e.g., 1:64 to 1:16) decline from baseline nontreponemal antibody titers or 
seroreversion to nonreactive.1 The Centers for Disease Control and Prevention (CDC) 
initially described the appropriate serological treatment response in the 1993 Sexually 
Transmitted Diseases (STD) Treatment Guidelines based on a study by Brown, et al.,2 which 
defined a four-fold decrease in Venereal Disease Research Laboratory (VDRL) titers at 3 
months as clinical cure after treatment of primary or secondary syphilis. The rate of 
seroreversion was reported in other studies to vary between 44% – 97% for primary syphilis, 
22 – 84% for secondary syphilis, and 13 – 73% for early latent syphilis at 12 months 
following therapy.3–5
Clinical and serological follow-up after treatment of early syphilis are recommended at 3, 6, 
9, 12, and 24 months for HIV-infected persons, and at 6 and 12 months for HIV-negative 
persons.1 More frequent evaluation is also recommended if the likelihood of follow-up is 
uncertain or repeat infection is a concern.1 Despite a ≥ 4-fold decline in nontreponemal 
antibodies after treatment, some patients will have persistent low-level titers over time with 
lack of complete seroreversion. In the absence of symptoms or possible re-infection, there is 
considerable uncertainty regarding the clinical significance of patients with persistent 
nontreponemal antibody titers despite achieving at least a 4-fold decline following therapy, 
which is especially problematic when a history of prior syphilis treatment or previous 
nontreponemal titers are not well documented. These patients may undergo unnecessary 
evaluations, additional therapy, or follow-up visits for serological monitoring.
Characterizing the expected serological outcomes after effective syphilis treatment is thus 
important to improving our understanding and interpretation of nontreponemal antibody 
titers following therapy. We previously published data from a randomized controlled trial 
(RCT) for treatment of early syphilis with benzathine penicillin versus azithromycin 
involving HIV-negative participants and analyzed their serological outcomes after therapy.6 
The majority of 465 participants (79.4%) achieved serological cure with similar cure rates at 
6 months between treatment arms.7 In order to evaluate the expected decline in 
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nontreponemal antibody titers and rate of complete seroreversion to nonreactive tests after 
effective therapy, we conducted further analyses of RCT participants who exhibited an 
appropriate serological response within 6 months of treatment.
Materials and Methods
We analyzed data from an open-label, RCT of syphilis treatment among HIV-negative 
patients age ≥ 18 years conducted from June 2000 to March 2009 at five sexually 
transmitted disease clinics in the U.S. and three clinics in Madagascar.6 Eligible patients 
were classified with primary, secondary, or early latent syphilis according to standard 
criteria,8 and underwent treatment randomization to 2.4 million units of benzathine PCN 
intramuscular injection or azithromycin 2.0 grams orally as directly observed therapy. The 
master study protocol was approved by the institutional review boards at the University of 
Alabama at Birmingham and study sites.
Rapid plasma reagin (RPR) titers were obtained at 1, 3, 6, 9 and 12 months after treatment; a 
subset of patients completed 18 and 24 month follow-up visits after treatment. An 
appropriate serological response to treatment in the primary study was defined as a ≥ 4-fold 
(2 dilutions) decrease in RPR titer and/or complete seroreversion at 6 months, defined as a 
non-reactive RPR after therapy. Patients who exhibited an initial ≥ 4-fold decline after 
therapy but had persistently positive low-level nontreponemal antibody titers were 
considered as serological responders who failed to exhibit seroreversion.
For this analysis, we evaluated participants from the parent study who exhibited a ≥ 4-fold 
serological titer response at 6 months as previously described by Seña, et al.7 and had at 
least 12 months of follow-up. We did not include data from study participants who had < 4-
fold decline in RPR titers after therapy reported in our prior study,6,7 because our objective 
was to evaluate the rate of decline and complete seroreversion among those with an 
appropriate treatment response. In order to plot the rate of titer decline after treatment, we 
divided the RPR titers obtained at each time point after therapy by the baseline titer to 
generate decimal values. A 4-fold decline in titers corresponded to a value of 0.25 (e.g. 3 
month titer of 1:8 with baseline titer at 1:32 resulting in 8/32 =0.25), whereby ≥ 8-fold 
decline in titers correspond to values ≤0.125. The decline in titer ratios were then evaluated 
using box plots for visualization (Figure).
To assess demographic and clinical characteristics associated with seroreversion, bivariate 
analyses were conducted using odds ratios (OR) and 95% confidence intervals (CI). Model 
development for characteristics associated with seroreversion was conducted by considering 
a large set of models, including and excluding variables and using the Akaike information 
criterion (AIC) to develop the final model.9 The final model was then checked using both 
forward and backward stepwise selection process to confirm the variable selection process. 
Adjusted odds ratios (AOR) and estimated 95% CIs are presented in Table 2.
Results
Figure 1 illustrates the flow diagram of HIV-negative participants who were treated for early 
syphilis in our study, and had serological data over a 12 month period following therapy. 
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There were 369 participants who exhibited at least a 4-fold decline in RPR titers at 6 months 
after treatment, of which 344 had serological data at the 12 month visit. After excluding 7 
participants with incomplete data during follow-up, and 4 participants who had re-infection, 
we analyzed data from 333 participants who had an appropriate serological treatment 
response and complete RPR data for each study visit over 12 months. Among these 
participants, only 9.6% achieved complete seroreversion at 6 months following treatment 
(Table 1); at 12 months, this proportion increased to only 17.1%, with the majority of 
participants characterized as serological responders who failed to exhibit seroreversion. The 
median RPR titer among the 276 patients who did not have seroreversion was 1:2 (range 1:1 
– 1:1024) at 12 months after treatment; 13.0% of patients still had persistent titers at ≥ 1:16. 
The proportion of participants who had seroreversion at 12 months was highest at 37.2% 
(32/86) among patients with primary syphilis, and lowest among those with secondary 
syphilis at 10% (17/170); there were no differences in the proportion of seroreversion 
between secondary and early latent syphilis groups.
When we plotted RPR titer decreases from baseline titers by month after therapy (Figure 2), 
a 2-fold decline in titers was already evident by one month after treatment (corresponding to 
a value of 0.5). Eighty-eight percent (293/333) of participants had a ≥ 4-fold decline at 3 
months after treatment and 77.8% had a ≥ 8-fold among at 6 months, irrespective of baseline 
RPR titers. The median decline in RPR titers was at least 8-fold (≤ 0.125) by 6 months 
following therapy, although there were variations in this titer change and outliers up to 24 
months after treatment.
Bivariate analyses (Table 2) showed that patient gender, syphilis stage, and baseline RPR 
titers were each associated with an increased likelihood of complete seroreversion at 12 
months. Male participants with early syphilis had a higher odds of achieving seroreversion 
(OR 4.4; 95% CI: 2.0–9.6) than female participants. Primary syphilis patients had a five-fold 
higher odds for seroreversion (OR 5.1; 95% CI: 2.3–12.7) compared to those with early 
latent or secondary syphilis infection. Patients with baseline RPR titers ≤ 1:32 had a 
significantly higher odds for seroreversion (OR 13.3; 95% CI: 6.5–27.1) compared to those 
with titers > 1:32.
After adjusting for the effects of gender, race, syphilis stage, baseline titer and syphilis 
treatment in the multivariate analyses, a higher odds (AOR 4.3, 95% CI: 1.8, 10.5) for 
seroreversion was found among men compared to women. Additionally, patients with 
baseline RPR titers ≤ 1:32 had an AOR of 14.5 (95% CI: 6.8, 31.2) for seroreversion at 12 
months compared to patients with baseline titers > 1:32.
Discussion
Among HIV-negative patients with early syphilis who demonstrated an appropriate 
serological treatment response in the six months following therapy, our study demonstrates 
that a 4-fold decline in RPR titers can occur as early as one month after therapy, and an 8-
fold decline as early as 6 months following therapy. The rate of decline appeared to be 
steepest in the first 3 months following treatment in our study population. This finding 
generally supports the current treatment guidelines regarding the time points for serological 
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monitoring and expected declines in nontreponemal antibody titers following therapy. 
However, complete seroreversion occurred in only 17% of early syphilis patients overall by 
12 months after treatment. Male gender, primary syphilis stage and lower baseline RPR 
titers were associated with higher odds of seroreversion.
Nontreponemal tests measure IgM and IgG antibodies to lipoidal antigens, principally 
cardiolipin, released from damaged host cells and T. pallidum, whose lipid composition is 
13% cardiolipin.10–11 Nontreponemal antibody titers tend to correlate with disease activity 
and are generally higher during early syphilis than during later stages of infection.12 
Seroreversion, or the reversion of nontreponemal tests from positive to negative results, was 
predominantly used by early syphilologists as an indicator of effective treatment.13 Brown, 
et al. was the first to evaluate the exponential decline in nontreponemal titers in 1985 among 
202 patients after treatment of early syphilis.2 In addition to demonstrating up to an 8-fold 
decline in VDRL titers at 6 months after therapy, they also noted a relationship between 
duration of syphilis, non-treponemal titers, and serological response, in which seroreversion 
was more rapid when there was a shorter duration of infection and a lower initial VDRL 
titer.2,5
Some of the earlier studies suggested that seroreversion occurred in the majority of patients 
by 1–2 years after treatment of primary and secondary syphilis.14–15 However, the patients 
in these studies were treated with 4.8 million units of benzathine PCN and were monitored 
serologically with the VDRL, which may have differences in quantitative titers relative to 
the RPR. Romanowski, et al.5 noted lower rates of complete seroreversion similar to our 
findings, reporting that only 43.9% seroreverted with primary syphilis, 21.6% with 
secondary syphilis, and 13.7% with early latent syphilis at 12 months after treatment. These 
investigators observed higher proportions of seroreversion at 36 months after therapy for 
71.9%, 56.3%, and 26.1% of patients with primary, secondary, and early latent syphilis, 
respectively. However, the proportion of participants with available RPR titers at ≥ 12 
months following therapy was only 41% in this retrospective study.5 We had data on some of 
our patients up to 24 months after therapy; however, the number with available RPR titers 
beyond 12 months was relatively small which limited our ability to assess seroreversion rates 
over a longer period of time.
We found higher odds of complete seroreversion among patients with primary syphilis 
compared to secondary or early latent syphilis in the bivariate analyses, and among 
participants with lower baseline RPR titers compared to higher titers in both the bivariate 
analysis and adjusted model. The relationship between seroreversion and stage of syphilis is 
not surprising since several studies have found an association between earlier stage of 
syphilis and serological treatment response.16 Romanowski, et al.5 also demonstrated that 
seroreversion rates depended on syphilis stage and baseline RPR titers, in which patients 
with higher initial titers (>1:8) were less likely to serorevert in primary and secondary 
syphilis. A subsequent analysis of their data further showed that individual serologic 
response appeared to be a linear function of (log) time, in which the slope of the response 
line in the first year following therapy was an important predictor of seroreversion along 
with the pre-treatment titer.17
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In contrast, other studies have reported that higher baseline titers (e.g., ≥ 1:32) are 
significantly associated with a greater likelihood of achieving serological cure among both 
HIV-infected and HIV-uninfected patients.5, 8, 18–23 Therefore, our findings of an inverse 
relationship, in which participants with RPR titers ≤ 1:32 had more than a 10-fold higher 
likelihood of seroreversion after therapy, further complicates the hypotheses regarding the 
significance of nontreponemal antibody titers during active syphilis infection. Investigators 
have suggested that persistent nontreponemal antibody titers following therapy may be due 
to a lingering benign immune response rather than due to residual T. pallidum in the host.16 
Translational studies are therefore necessary to investigate these hypotheses and the 
correlation of quantitative nontreponemal antibody titers with organism burden and the 
immune response.16 Conducting these studies would be challenging but crucial to our 
understanding of the antibody responses in patients with syphilis infection before and after 
treatment.
We also found that male participants, which represented 63.1% of our study population, had 
a higher likelihood of seroreversion than female patients; however, no associations were 
noted between participants’ race, treatment arm, and likelihood of seroreversion. A 
systematic review of other studies evaluating factors that affect serological treatment 
outcomes reported conflicting results regarding the effect of patient age or gender on these 
outcomes.16 We found a low rate of seroreversion among HIV-negative patients with early 
syphilis enrolled from our multicenter study, which may not be generalizable to the syphilis 
infected population in the US comprised primarily of MSM of whom 51.2% are HIV-
infected.24 However, only two out of nine studies investigating the effect of HIV infection 
on serological treatment outcomes reported that HIV-infection decreased the likelihood and 
time to serological cure.16,19,25 Based on these findings, HIV-infected patients with early 
syphilis may experience a similar decline in RPR titers or rate of seroreversion after 
treatment.
The 2015 CDC STD Treatment Guidelines states that clinical and serologic evaluation 
should be performed at 6 and 12 months after treatment of primary and secondary syphilis, 
and at 6, 12, and 24 months for latent syphilis.1 We used a more stringent criteria of a ≥ 4-
fold decline at 6 months due to the initial design of the clinical trial.6 Therefore, our findings 
represent the response that would be characteristic of patients with a more rapid treatment 
response, and not all patients who may subsequently exhibit a 4-fold decline in 
nontreponemal antibody titers at ≥ 12 months after therapy. We did not assess the rate of 
seroreversion among patients with late latent syphilis in our study, so additional prospective 
studies involving diverse populations with longer follow-up periods would be ideal to 
determine clinical outcomes among persons with persistent nontreponemal antibody titers 
following therapy. Lastly, patients with a history of prior syphilis infection may have a 
different rate of seroreversion after treatment, but only 17 of our participants had a syphilis 
history limiting our ability to assess this variable in our analyses.
Based on our findings, clinicians should be aware that most patients who exhibit ≥ 4-fold 
decline in nontreponemal antibody titers in the first year after treatment for early syphilis 
may continue to have reactive serological tests over time. Longer periods of serological 
monitoring would be required if complete seroreversion after syphilis treatment should be 
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the desired outcome; however, the benefits of such an approach are unproven and unlikely to 
be significant when an appropriate treatment response has already been documented. Given 
that only a small proportion of patients have seroreversion after an appropriate serological 
treatment response, follow-up serological monitoring may not be necessary for all patients 
who already demonstrate a 4-fold decline in titers. The need for follow-up periods longer 
than one year should be determined on a case-by-case basis depending on resources, patient 
compliance and risk for subsequent reinfections.
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Flow diagram of study participants treated for early syphilis who had an appropriate 
serological response after therapy and serological data over a 12 month period included in 
this analyses.
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Box plots of decrease in nontreponemal antibody titers based on baseline RPR titers and 
month (s) after therapy (x-axis). Decline in titers were represented as decimal values in the 
y-axis, in which 0.5 indicated a 2-fold decline in titers (e.g. 1:16 at one month divided by 
baseline titer of 1:32, or 16/32=0.5); 0.25 indicated a 4-fold decline; and 0 indicated 
seroreversion. The box for each baseline titer represented the 25–75th interquartile range, 
with lines indicating the median value for decline in titers. Each panel also illustrates the 
range of values outside of the intra-quartile range (whiskers) and outliers (circles) for each 
baseline titer. The number of observations that corresponded to the baseline titers are 
included at the bottom of each panel.
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Table 1
Proportion of patients with seroreversion (negative RPR) after a ≥ 4-fold decline in nontreponemal antibody 
titers following syphilis treatment, according to stage of infection and time after therapy.
Stage of syphilis 3 months 6 months 9 months 12 months
Primary (n=86) 9 (10.5%) 20 (34.9%) 30 (34.9%) 32 (37.2%)
Secondary (n=170) 1 (0.6%) 7 (4.1%) 10 (5.9%) 17 (10.0%)
Early latent (n=77) 5 (6.5%) 5 (6.5%) 8 (10.4%) 8 (10.4%)
Total early syphilis (N=333) 15 (4.5%) 32 (9.6%) 48 (14.4%) 57 (17.1%)
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Table 2
Bivariable analyses of characteristics among participants who exhibited seroreversion versus persistent 
nontreponemal antibody titers at 12 months (despite an appropriate serological treatment response), and 
adjusted model for characteristics associated with seroreversion.
Characteristics Seroreversion within 12 Months Reactive RPR at 12 Months OR (95% CI) AOR (95% CI)
Male 49 (23.3 %) 161 (76.7 %) 4.4 (2.0, 9.6) 4.3 (1.8, 10.5)
Female 8 (6.5 %) 115 (93.5 %) * *
Malagasy 42 (15.1%) 237 (85.0 %) 0.4 (0.1, 1.7) 0.2 (0.1, 1.3)
Black 12 (26.7 %) 33 (73.3 %) 0.7 (0.2, 3.9) 0.8 (0.1, 4.7)
White + other 3 (33.3 %) 6 (66.7 %) * *
Stage: Primary 32 (37.2 %) 54 (62.8 %) 5.1 (2.3, 12.7) -----
Stage: Secondary 17 (10.0 %) 153 (90.0 %) 1.0 (0.4, 2.4) -----
Stage: Early Latent 8 (10.4 %) 69 (89.6 %) * -----
Baseline RPR Titers ≤ 1:32 46 (41.1 %) 66 (58.9 %) 13.3 (6.5, 27.1) 14.5 (6.8, 31.2)
Baseline RPR Titers > 1:32 11 (5.0 %) 210 (95.0 %) * *
Penicillin 32 (19.1 %) 136 (81.0 %) 1.3 (0.7, 2.3) -----
Azithromycin 25 (15.2 %) 140 (84.9 %) * -----
RPR= rapid plasma reagin; OR= odds ratio based on bivariate results; CI, confidence interval; AOR= adjusted odds ratio based on model
*
Reference category
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